AML, Childhood Clinical Trial
Official title:
A Phase 1, Open-label, Dose-escalation Trial of CD33xCD3 Bispecific Antibody in Pediatric Patients With Relapsed or Refractory Acute Myeloid Leukemia
Pediatric patients (<21 years at study entry) with relapsed or refractory acute myeloid leukemia (AML) will be treated with CD33*CD3 a bispecific antibody to investigate the safety and tolerability of the drug.
This is an open label, first in human dose escalation trial in pediatric patients with relapsed or refractory acute myeloid leukemia to assess the safety and tolerability of increasing doses of CD33xCD3 BsAb administered subcutaneously. A modified Bayesian Optimal Interval Design (mBOIN) design will be applied. The trial will start with accelerated titration using single patient cohorts until one grade ≥2 AE not clearly associated to underlying disease, thereafter the trial will continue with mBOIN titration. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Active, not recruiting |
NCT03825367 -
Nivolumab in Combination With 5-azacytidine in Childhood Relapsed/Refractory AML
|
Phase 1/Phase 2 | |
| Recruiting |
NCT06158828 -
Pilot Study of Memory-like Natural Killer (ML NK) Cells After TCRαβ T Cell Depleted Haploidentical Transplant in AML
|
Phase 1/Phase 2 | |
| Recruiting |
NCT06221683 -
Clinical Study of Induction Therapy Options Based on Molecular Subtyping and MRD in Children and Adolescents With AML
|
Phase 2 | |
| Recruiting |
NCT06316960 -
Safety and Efficacy of Avapritinib in Relapsed or Refractory Pediatric CBF-AML With KIT Mutation
|
Phase 2 | |
| Withdrawn |
NCT05622591 -
ELU001 in Pediatric Subjects Who Have Relapsed and/or Refractory CBFA2T3-GLIS2-positive AML
|
Phase 1 | |
| Recruiting |
NCT06326463 -
CAR T-cell Therapy Directed to CD70 for Pediatric Patients With Hematological Malignancies
|
Phase 1 | |
| Not yet recruiting |
NCT06389357 -
Return to School Adaptation Programme for Children With Cancer
|
N/A | |
| Terminated |
NCT04326439 -
AflacLL1901 (CHOA-AML)
|
Phase 2 |